Segment Information (Tables)

3 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended June 30,
	2023			2022
	(in thousands)
Segment Revenue: (1)
Consumer and Research Services	$	60,864		$	64,513
Total revenue	$	60,864		$	64,513
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(5,602	)	$	(16,997	)
Therapeutics Adjusted EBITDA		(31,138	)		(18,465	)
Unallocated Corporate (2)		(13,060	)		(14,253	)
Total Adjusted EBITDA	$	(49,800	)	$	(49,715	)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(104,624	)	$	(89,532	)
Adjustments:
Interest income, net		(4,307	)		(245	)
Other (income) expense, net		(333	)		435
Income tax benefit		—			(254	)
Depreciation and amortization		4,478			5,104
Amortization of acquired intangible assets		3,638			4,315
Stock-based compensation expense		51,100			30,462
Transaction-related costs (3)		248			—
Total Adjusted EBITDA	$	(49,800	)	$	(49,715	)

(1)There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022.

(2)Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.

(3)Refer to Note 17, “Subsequent Events” for additional information.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended June 30,
	2023				2022
	(in thousands)
Consumer and Research Services Segment Revenue:
Customer C (1) (2)	$	9,711	16	%	$	9,628	15	%
Customer B (3)	$	10,670	18	%	$	8,246	13	%

(1)Customer C is a reseller.

(2)Customer C revenues are primarily in the United States.

(3)Customer B revenues are in the U.K.